NICM
XENE icon

Neo Ivy Capital Management’s Xenon Pharmaceuticals XENE Stock Holding History

Neo Ivy Capital Management’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$797K Buy
13,710
+6,233
+83% +$287K 0.21% 173
2025
Q4 		$335K Sell
7,477
-42,361
-85% -$1.78M 0.05% 224
2025
Q3 		$2M Buy
+49,838
New +$1.76M 0.49% 71

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Neo Ivy Capital Management's XENE Position: Q1 2026 in Review

Neo Ivy Capital Management increased its Xenon Pharmaceuticals (XENE) stake by 83% in Q1 2026, buying an estimated $287K and bringing the position to 13,710 shares worth $797K. The position accounts for 0.21% of the portfolio, ranked #173.

Neo Ivy Capital Management first reported a position in XENE in Q3 2025 and has held it in 3 quarters since. The position peaked at $2M in Q3 2025. 290 funds tracked by Wall St. Rank hold XENE as of Q1 2026.

  • Neo Ivy Capital Management held 13,710 shares of Xenon Pharmaceuticals worth $797K as of Q1 2026.
  • Neo Ivy Capital Management bought 6,233 Xenon Pharmaceuticals shares in Q1 2026, an estimated $287K.
  • Xenon Pharmaceuticals made up 0.21% of Neo Ivy Capital Management's portfolio in Q1 2026, its #173 holding.
  • Neo Ivy Capital Management first reported a position in Xenon Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • Neo Ivy Capital Management's Xenon Pharmaceuticals position peaked at $2M in Q3 2025.
  • 290 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2026.

Based on Neo Ivy Capital Management's 13F filing for Q1 2026, filed 15 May 2026.